Hyperfine Inc. (HYPR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Hyperfine Q1 Earnings Call Highlights
Hyperfine NASDAQ: HYPR reported a sharp year-over-year increase in first-quarter revenue and reiterated its full-year 2026 outlook, as management pointed to continued adoption of its next-generation Swoop portable MRI system across hospitals, neurology offices and international markets.
Hyperfine, Inc. (HYPR) Reports Q1 Loss, Beats Revenue Estimates
Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.12 per share a year ago.
Hyperfine, Inc. (HYPR) Q4 2025 Earnings Call Transcript
Hyperfine, Inc. (HYPR) Q4 2025 Earnings Call Transcript
Analyzing Hyperfine (NASDAQ:HYPR) and Arrayit (OTCMKTS:ARYC)
Hyperfine (NASDAQ: HYPR - Get Free Report) and Arrayit (OTCMKTS:ARYC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability. Valuation and Earnings This table compares Hyperfine and Arrayit"s revenue,
Hyperfine, Inc. (HYPR) Q3 2025 Earnings Call Transcript
Hyperfine, Inc. ( HYPR ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Webb Campbell Maria Sainz - CEO, President & Director Brett Hale - Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to Hyperfine's Third Quarter 2025 Earnings Conference Call.
Hyperfine, Inc. (HYPR) Reports Q3 Loss, Tops Revenue Estimates
Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
Hyperfine (HYPR) Upgraded to Buy: Here's Why
Hyperfine (HYPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hyperfine, Inc. (HYPR) Q2 2025 Earnings Call Transcript
Hyperfine, Inc. (NASDAQ:HYPR ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Brett Hale - Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary Maria Sainz - CEO, President & Director Conference Call Participants Brandon Carney - B. Riley Securities, Inc., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Webb Campbell - Unidentified Company Operator Good afternoon, and welcome to Hyperfine's Second Quarter 2025 Earnings Conference Call.
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
HYPR secures FDA clearance for its next-gen Swoop system, advancing bedside MRI tech and reinforcing its mission to revolutionize accessible neuroimaging.
